Logo Image
|Articles|June 9, 2021

Supplements and Featured Publications

  • Moderate to Severe Psoriasis: Considerations for Patient Management Amid a Changing Treatment Spectrum
  • Volume 27
  • Issue 10

Participating Faculty for Moderate to Severe Psoriasis: Considerations for Patient Management Amid a Changing Treatment Spectrum

FACULTY

Jerry Bagel, MD, MS

Director

Psoriasis Treatment Center of New Jersey

East Windsor, New Jersey

Clinical Professor

Icahn School of Medicine at Mount Sinai

New York, New York

FACULTY DISCLOSURES

Jerry Bagel, MD, MS, has disclosed the following relevant commercial financial relationships or affiliations in the past 12 months:

BOARD MEMBERSHIP

The National Psoriasis Foundation, Board of Directors

CONSULTANCIES OR PAID ADVISORY BOARDS

AbbVie, Janssen Pharmaceuticals, Arcutis Biotherapeutics

GRANTS RECEIVED

AbbVie, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly and Company, Novartis,
Sun Pharma, UCB

LECTURE FEES FOR SPEAKING AT THE INVITATION OF A COMMERCIAL SPONSOR

AbbVie, Eli Lilly and Company, Janssen Pharmaceuticals

Download PDF

Articles in this issue

over 5 years ago

Treatment Strategies, Management of Comorbidities, and the Role of IL-23 Inhibitors in Moderate to Severe Psoriasis

Related to this article

View more
Daniel Kyung Min, PharmD | Image: LinkedIn
High-Intensity IV Iron Replacement for Chronic Bleeding in HHT: A Case Series
The article explores the use of dose-intensive IV iron replacement to achieve long-term hemoglobin stability in patients with moderate to severe HHT-related bleeding. The approach recognizes what the author calls "the relentless and recurrent nature of HHT-associated bleeding," and may help patients achieve better quality of life.
Read more